Trial · NCT07911046
Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent Obesity
NCT07911046, Not yet recruiting, Erin Mauney
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent Obesity. Trials, record NCT07911046. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07911046
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent Obesity
- NCT number
- NCT07911046
- Status
- Not yet recruiting
- Enrollment
- 12 participants, estimated
- Lead sponsor
- Erin Mauney
- Conditions
- Pediatric Obesity, Obesity
- Interventions
- Semaglutide
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in resting-state functional connectivity in reward and default-mode networks | Baseline (pre-initiation) and approximately 6 months after semaglutide initiation | Within-subject change in resting-state functional connectivity within and between reward, default-mode, and salience networks, derived from 3T resting-state functional MRI and analyzed as network connectivity and graph metrics, from baseline to approximately 6 months of treatment. Measures are interpreted relative to normative data from the ABCD Study. |
| Secondary | Change in brain structure (hypothalamic and reward-region morphometry) | Baseline (pre-initiation) and approximately 6 months after semaglutide initiation | Within-subject change in brain structure derived from 3T structural MRI, including hypothalamic and reward-related region volume and morphometry, from baseline to approximately 6 months of treatment. |
| Secondary | Change in fluid cognition (NIH Toolbox Cognition Battery) | Baseline (pre-initiation) and approximately 6 months after semaglutide initiation | Within-subject change in fluid cognition measured with the NIH Toolbox Cognition Battery (fluid subset), from baseline to approximately 6 months of treatment. |
| Secondary | Change in eating behavior and food-related reward | Baseline (pre-initiation) and approximately 6 months after semaglutide initiation | Within-subject change in eating behavior, food-related reward, and food preoccupation ("food noise") measured by validated self-report instruments, from baseline to approximately 6 months of treatment. |
| Secondary | Change in interoceptive awareness (MAIA-2) | Baseline (pre-initiation) and approximately 6 months after semaglutide initiation | Within-subject change in interoceptive awareness measured with the Multidimensional Assessment of Interoceptive Awareness, Version 2 (MAIA-2), from baseline to approximately 6 months of treatment. |
| Secondary | Change in blood- and saliva-based biomarkers | Baseline (pre-initiation) and approximately 6 months after semaglutide initiation | Within-subject change in a panel of blood- and saliva-based biomarkers, including adipokines (e.g., leptin, adiponectin), inflammatory markers, neurotrophic factors, and appetite-regulating hormones, from baseline to approximately 6 months of treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07911046
GET https://conductscience.org/api/trials/v1/NCT07911046/registered